• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?2005年靶向治疗进展国际研讨会：我们在21世纪学到了什么，又将走向何方？
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv106-8. doi: 10.1136/ard.2005.042408.
2
[Chinese expert-based consensus for methotrexate in rheumatic diseases].[中国风湿性疾病甲氨蝶呤专家共识]
Zhonghua Nei Ke Za Zhi. 2018 Oct 1;57(10):719-722. doi: 10.3760/cma.j.issn.0578-1426.2018.10.005.
3
[Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].[德国风湿病学会药物治疗委员会建议的修订。肿瘤坏死因子阻滞剂治疗炎性风湿性疾病]
Z Rheumatol. 2007 Feb;66(1):72-5. doi: 10.1007/s00393-006-0132-6.
4
[TNF-alpha antagonists in therapy of rheumatoid arthritis].[肿瘤坏死因子-α拮抗剂在类风湿关节炎治疗中的应用]
Z Rheumatol. 2003 Jun;62(3):217.
5
Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.在使用甲氨蝶呤和肿瘤坏死因子抑制剂治疗后仍持续存在活动性类风湿关节炎的患者中，加用他克莫司的长期疗效和安全性。
Int J Rheum Dis. 2018 Mar;21(3):673-687. doi: 10.1111/1756-185X.13248. Epub 2018 Jan 4.
6
Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.类风湿关节炎：抗风湿治疗的选择。首选甲氨蝶呤。
Prescrire Int. 2010 Feb;19(105):30-4.
7
Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?风湿病与自身免疫领域大师的观点：我们能否更接近治愈类风湿关节炎？
Arthritis Rheumatol. 2015 Sep;67(9):2283-91. doi: 10.1002/art.39269.
8
Proceedings of the XIIth International Symposium on Advances in Targeted Therapies. April 14-18, 2010.第十二届靶向治疗进展国际研讨会会议记录。2010年4月14日至18日。
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i1-122.
9
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.新型靶向疗法：类风湿关节炎的未来？以马夫珠单抗和塔巴珠单抗为例。
Ann Rheum Dis. 2013 Sep 1;72(9):1433-5. doi: 10.1136/annrheumdis-2013-203261. Epub 2013 Apr 26.
10
Neutropenia in the Elderly: A Rheumatology Perspective.老年人中性粒细胞减少症：风湿病学视角
Drugs Aging. 2016 Aug;33(8):585-601. doi: 10.1007/s40266-016-0383-0.

引用本文的文献

1
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.用托珠单抗抑制白细胞介素-6受体可改善对抗肿瘤坏死因子生物制剂难治的类风湿关节炎患者的治疗效果：一项为期24周的多中心随机安慰剂对照试验的结果
Ann Rheum Dis. 2008 Nov;67(11):1516-23. doi: 10.1136/ard.2008.092932. Epub 2008 Jul 14.

2005年靶向治疗进展国际研讨会：我们在21世纪学到了什么，又将走向何方？

The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?

作者信息

Maini R N

机构信息

Kennedy Institute of Rheumatology Division, Imperial College, London.

出版信息

Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv106-8. doi: 10.1136/ard.2005.042408.

DOI:10.1136/ard.2005.042408
PMID:16239377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1766915/
Abstract

This essay summarises a personal perspective on where we have got to in the five years since the turn of the last century. The focus is on advances in knowledge of antitumour necrosis factor (anti-TNF) therapy of rheumatoid arthritis and other chronic immune-inflammatory rheumatic diseases. The accumulating knowledge is clarifying the scope and limitations of efficacy, safety, and durability of these agents. It is defining the unmet needs of patients and communities worldwide for the future. The call is for progress in providing more cost-effective advances in therapeutics that not only interrupt the disease process long term but also reverse the anatomical and functional consequences of disease and the impairment in quality of life.

摘要

本文总结了自上世纪之交以来的五年里我们所处状况的个人观点。重点是类风湿关节炎及其他慢性免疫炎症性风湿疾病的抗肿瘤坏死因子（抗TNF）治疗方面的知识进展。不断积累的知识正在阐明这些药物在疗效、安全性和持久性方面的范围及局限性。它正在明确全球患者和群体未来未满足的需求。呼吁在提供更具成本效益的治疗进展方面取得进步，这些进展不仅要长期中断疾病进程，还要逆转疾病的解剖学和功能后果以及生活质量受损的情况。